Cellectar Biosciences, Inc. Annual report pursuant to Section 13 and 15(d)

RESTATEMENT OF PREVIOUSLY ISSUED CONSOLIDATED FINANCIAL STATEMENTS (Details 1) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Consolidated Statement of Operations Data:
Gain on revaluation of derivative warrants	$ 2,285,157	$ 2,373,941
Total other income, net	1,838,843us-gaap_NonoperatingIncomeExpense	1,619,636us-gaap_NonoperatingIncomeExpense
Net loss	(8,052,102)us-gaap_NetIncomeLoss	(10,782,168)us-gaap_NetIncomeLoss
Basic and diluted net loss per common share	$ (1.75)us-gaap_EarningsPerShareBasicAndDiluted	$ (3.86)us-gaap_EarningsPerShareBasicAndDiluted
Scenario, Previously Reported [Member]
Consolidated Statement of Operations Data:
Gain on revaluation of derivative warrants	2,230,864
Total other income, net	1,784,550
Net loss	(8,106,395)
Basic and diluted net loss per common share	$ (1.77)
Restatement Adjustment [Member]
Consolidated Statement of Operations Data:
Gain on revaluation of derivative warrants	54,293
Total other income, net	54,293
Net loss	$ 54,293
Basic and diluted net loss per common share	$ 0.01

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.